RE: No abuse please14 Apr 2021 13:02
This is from the business update 24th Feb RNS:
Depending on your view of around end of quarter, CV and CE news is imminent/overdue and European sales are dependent on CE mark. So as soon as CE mark is obtained I would say revenues are inbound. Can't imagine after such a positive initial CV, AVCT havent been manufacturing tests ready for the "regulatory" green light
"During the past year Avacta, in conjunction with its partners, has made exciting progress in the development of its Affimer based, SARS-CoV-2 lateral flow rapid antigen test. Laboratory studies indicate that it may be the most sensitive S1 spike protein lateral flow test available [to date]. Furthermore, recently announced data from initial clinical samples has shown a sensitivity of 96.7% for patient samples with an infectious viral load, and specificity of 100%. On the basis of these excellent data, the Group is now progressing to a full clinical validation with a larger number of patient samples to CE mark the test for professional use, aiming to bring the test to market in Europe around the end of the first quarter of this year."